In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...
Read More
In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...
Read More
In a nutshell This study investigated the outcomes of umbilical cord blood transplantation in pretreated patients with Hodgkin’s lymphoma. The authors concluded that this procedure is a feasible treatment option for these patients. Some background Patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma have...
Read More
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) compared with standard chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). The study found that blinatumomab was a safe and effective treatment option compared to chemotherapy in patients with ALL. Some background Acute lymphoblastic leukemia is...
Read More
In a nutshell This study examined the role of allogeneic hematopoietic stem cell transplantation in multiple myeloma. The study determined that allogeneic stem cell transplant is feasible for patients who have previously received other treatment. Some background Survival of patients with multiple myeloma has improved with the development of new...
Read More
In a nutshell This study looked at the targeted therapy osimertinib (Targrisso) and its effectiveness at managing disease symptoms in patients with lung cancer. The study concluded that osimertinib was more effective than chemotherapy at improving disease symptoms in these patients. Some background New anti-cancer drugs target specific genetic...
Read More
In a nutshell This study examined the effectiveness of encorafenib (Braftovi) alone or in combination with binimetinib or vemurafenib (Zelboraf) alone in BRAF-mutant melanomas. Researchers suggested that the combined treatment showed improved cancer outcomes with manageable side effects. Some background Some melanoma patients have a...
Read More
In a nutshell This study aimed to measure the effectiveness of bendamustine and rituximab as salvage treatment in patients with chronic lymphocytic leukemia. This study concluded that bendamustine and rituximab are as effective as ibrutinib as salvage treatment in these patients. Some background The standard treatment for chronic lymphocytic...
Read More
In a nutshell This paper reviewed the effect of elozutumab (Empliciti) in the treatment of relapsed or refractory multiple myeloma. This study concluded that elozutumab with lenalidomide (Revlimid) and dexamethasone (Ozurdex) can be considered in relapsed or refractory multiple myeloma. Some background Multiple myeloma...
Read More
In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients. Some background Chronic lymphocytic leukemia...
Read More
In a nutshell This study determined the real-world outcomes for patients with relapsed or refractory Hodgkin’s lymphoma (rrHL) who were given brentuximab vedotin (Adcetris) due to ineligibility for autologous stem cell transplant (ASCT). The study concluded that brentuximab vedotin is feasible and effective in patients with rrHL who are...
Read More
In a nutshell This phase 3 trial aims to determine the effectiveness of Iomab-B before an hematopoietic stem cell transplantation compared to conventional treatment. The outcome to be measured is remission (no disease) and survival. The details Acute myeloid leukemia is a type of bone marrow cancer. Iomab-B is a drug in development for...
Read More
